Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you live in Essex and you've been looking into weight loss injections, you've probably already worked out that the two licensed options in the UK are tirzepatide (Mounjaro) and semaglutide (Wegovy). Both are once-weekly subcutaneous injections, prescription-only medicines, and available through a regulated private pharmacy without the NHS waiting list — provided a prescriber decides you're clinically suitable. Where you live doesn't change the medicines, the eligibility criteria, or the process; it changes whether you're trying to find a local clinic or whether an online pharmacy that dispatches to your front door makes more practical sense. For many Essex residents, it turns out to be the latter.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You've probably spent time reading about these medicines, possibly had a conversation with your GP that didn't quite go where you hoped, and now you're weighing up your options. That frustration is real. NHS prescribing for tirzepatide is still rolling out in phases, as of mid-2026, the criteria are strict, and many people who'd clearly benefit don't yet qualify for the NHS route. A private prescription through a registered online pharmacy is the most practical alternative for a significant number of Essex residents, and it's worth understanding exactly how that works.
Mounjaro and Wegovy are subcutaneous injections, meaning just under the skin, not into muscle. You inject into the abdomen, thigh, or upper arm, rotating the site each week. The pen comes pre-filled; there's no drawing up of liquid, no complicated technique. Most people find the process far less daunting than they expected. If you want to understand the broader landscape of licensed treatments before going further, the overview of weight loss injections covers the category in full.
The licensed eligibility criteria for private treatment are: adults with a BMI of 30 or above, or BMI 27 or above alongside at least one weight-related condition such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnoea. A prescriber looks at the whole picture, BMI is a starting point, not a guarantee either way.
In the SURMOUNT-1 trial, tirzepatide at its highest dose produced an average body-weight reduction of around 20–21% over 72 weeks in adults with obesity without diabetes, involving 2,539 participants. Semaglutide at 2.4mg produced approximately 15% average reduction over 68 weeks in the STEP 1 trial. In SURMOUNT-5, a direct head-to-head published in the New England Journal of Medicine in 2025, tirzepatide produced greater average weight loss than semaglutide 2.4mg. These are averages from tightly controlled trials; individual results vary, and neither medicine is a substitute for the dietary and lifestyle changes a prescriber will discuss with you.
The comparison of the three main injection options goes into the trial evidence in more detail if you want to weigh up the numbers side by side. What the trials can't tell you is which medicine suits your health profile, that's precisely what a clinical consultation is for.
NICE recommends tirzepatide for NHS use (TA1026) for adults with a BMI of 35 or above plus at least one weight-related comorbidity, with lower thresholds applying for some ethnic backgrounds. The private licensed threshold is lower (BMI 30, or 27 with a qualifying condition) which is why private routes are relevant to people who meet the licensed criteria but fall outside the current NHS cohort. You can check the GP prescribing page for a clearer picture of what's currently available through the NHS in primary care.
The most common side effects of both medicines are gastrointestinal, nausea, loose stools, constipation, indigestion, and reflux feature most often. They tend to peak after starting or after a dose increase, and for most people they ease within days to a couple of weeks as the body settles. Starting at the lowest dose and titrating gradually is specifically designed to reduce this burden; it's the reason the starter dose exists.
On injection technique: rotate your site each week, use a fresh needle each time, and clean the skin beforehand. Store your pen in the fridge between 2°C and 8°C; for exact guidance on travel windows and room-temperature limits, the Patient Information Leaflet that comes with your pen is the definitive source, not a forum, not a social media post. The injection guidance page covers technique in more detail.
Pancreatitis is a rare but serious risk. The MHRA issued a Drug Safety Update in January 2026 specifically flagging acute pancreatitis for GLP-1 medicines: severe, persistent stomach pain that reaches through to the back, with or without vomiting, needs urgent medical attention, don't wait for your next review. Any suspected side effects can be reported directly at the MHRA's Yellow Card scheme. And if you're ever unsure whether a symptom is normal or not, the right call is always to contact a clinician rather than sit on it.
Pregnancy, breastfeeding, and trying to conceive: these medicines are not recommended in any of those situations. Under-18s are not a licensed group. Women using oral contraceptives alongside tirzepatide should add a non-oral method for the first four weeks of treatment and for four weeks after each dose increase, because the pill's absorption may be affected, NHS England's guidance on weight-management injections covers this clearly.
There is no legitimate shortcut to these medicines. They are prescription-only. Anyone selling them without a valid prescription and clinical assessment is operating outside the law, and the MHRA has seized large quantities of counterfeit pens (some containing insulin rather than the stated medicine) from unverified online sellers. The red flags are consistent: no clinical assessment, prices far below what a licensed supply chain can sustain, and sometimes outright fake branding.
Before ordering from any online pharmacy, check it on the GPhC pharmacy register. Registration is verifiable in seconds and tells you the pharmacy is regulated and accountable. If you'd like to understand what an honest price range looks like before starting a consultation, the cost and pricing page sets out the market context plainly.
At nume, our pharmacy is GPhC-registered (registration number 9012878), and every consultation is read by a GPhC-registered Independent Prescriber, a named clinician, not automated decision-making. You can read more about how we work on the about us page, or explore the full range of weight loss treatments before starting your free consultation. If suitability is confirmed, your prescription is dispatched the same day for free next-working-day delivery by DPD, tracked, plain packaging, straight to your Essex address. We also have a dedicated page covering weight loss injections in Wales if you or someone you know is based there and wants to understand how the process works in that area. Check your eligibility whenever you're ready.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.